A detailed history of Boothbay Fund Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 30,600 shares of VRTX stock, worth $13.8 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
30,600
Holding current value
$13.8 Million
% of portfolio
0.4%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $511,038 - $636,296
2,175 Added 69.09%
5,323 $1.5 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $2.27 Million - $2.68 Million
-10,273 Reduced 76.54%
3,148 $822,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $112,401 - $141,890
635 Added 4.97%
13,421 $2.95 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $248,685 - $278,299
-1,371 Reduced 9.68%
12,786 $2.32 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $883,265 - $1.04 Million
4,711 Added 49.87%
14,157 $2.85 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $665,155 - $775,329
3,213 Added 51.55%
9,446 $2.03 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $1.29 Million - $1.72 Million
6,233 New
6,233 $1.47 Million
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $215,029 - $247,092
-1,282 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $126,922 - $148,035
-871 Reduced 40.46%
1,282 $218,000
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $62,610 - $73,154
413 Added 23.74%
2,153 $351,000
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $147,164 - $166,749
-1,072 Reduced 38.12%
1,740 $261,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $416,541 - $456,218
2,812
2,812 $428,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.